Security key
22407B108
Coya Therapeutics, Inc. - Common Stock, $0.0001 par value per share (COYA)
CUSIP: 22407B108
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 1,309,848
- Total 13F value
- $7,662,612
- Share change
- -262,859
- SEC-reported price per share
- $5.85
- Number of holders
- 15
- Value change
- -$1,529,787
- Number of buys
- 5
- Number of sells
- 4
- Shares outstanding
- 23,172,091
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
15
Top holders
10
COYA full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q4 2025
Coya Therapeutics, Inc. SEC filings
Coya Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 22407B108
Recent filing periods:
Ownership snapshot
Top reported holders of COYA - Coya Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
DME Capital Management, LP
Disclosed value leader
DME Capital Management, LP
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 9.9%
13D/G row: DME Capital Management, LP
Showing 1-6 of 15 holder rows.
Quick read
DME Capital Management, LP leads the comparable SEC ownership view at 9.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens DME Capital Management, LP's linked filing trail.
Comparable ownership
Top 5
DME Capital Management, LP
9.9%
Dr. Reddy's Laboratories, Inc.
9.7%
VANGUARD GROUP INC
4.3%
Orin Hirschman
3.3%
AIGH Capital Management LLC
4.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| DME Capital Management, LP |
13D/G
13F
DME Advisors GP, L.L.C. · Company
|
9.9%
|
$10,783,903
1,651,440 shares
|
$0 | 31 Dec 2024 |
| Dr. Reddy's Laboratories, Inc. |
13D/G
|
9.7%
|
$10,727,271
2,272,727 shares
|
$0 | 30 Jan 2026 |
| VANGUARD GROUP INC |
13D/G
The Vanguard Group
|
4.3%
|
$5,215,012
899,140 shares
|
$0 | 31 Dec 2025 |
| Orin Hirschman |
13D/G
|
3.3%
|
$4,473,372
764,679 shares
|
-$2,009,428 | 30 Jun 2026 |
| AIGH Capital Management LLC |
13F
Company
|
4.2%
|
$3,843,092
975,404 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3.6%
|
$3,328,957
844,913 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
15
Shares
1,309,848
Rows available
15
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q4 2025 Across Filers
Q4 2025 holders
58
Q2 2026 holders
15
Holder diff
-43
| Investor | Q4 2025 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend